EVALUATION OF LIVE ATTENUATED RESPIRATORY SYNTICIAL VIRUS VACCINE IN ADULTS

成人呼吸道合成病毒减毒活疫苗的评价

• 批准号: 6115584
• 负责人: PETER Farnum WRIGHT
• 金额: $ 3.64万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115584
• 关键词: adult human (21+); attenuated microorganism; child (0-11); clinical research; drug screening /evaluation; human subject; infant human (0-1 year); live vaccine; respiratory syncytial virus; viral vaccines

Evaluate the safety of the cp and ts RS virus vaccine strains in RS virus seropositive adults, the safety of candidate cp and ts vaccine strains in RS virus seropositive children, and the safety, infectivity, immunogenicity, genetic stability, transmissibility and ability of the candidate RS virus vaccines to induce protective immunity in RS virus seronegative infants and children. During the report period, 2 vaccines was evaluated in a total of 15 seropositive children, and 16 seronegative children. No adverse events have occurred. Enrollment is ongoing.

评估RS病毒中CP和TS RS病毒疫苗菌株的安全性 血清阳性成年人，候选CP和TS疫苗菌株的安全性 在RS病毒血清阳性儿童以及安全性，感染力中 免疫原性，遗传稳定性，可传染性和能力 候选RS病毒疫苗可诱导RS病毒的保护性免疫 血清神经婴儿和儿童。在报告期间，2种疫苗 在总共15个血清阳性儿童和16个血清神经中评估 孩子们。没有发生不良事件。入学率正在进行。